Innate Pharma to participate in the Jefferies Global Healthcare Conference
Innate Pharma to participate in the Jefferies Global Healthcare Conference
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced that members of its executive team will participate in one-on-one investor meetings at the following conference:
Jefferies Global Healthcare Conference 2026
Dates: June 2–4, 2026
Regulatory tracker: Taiho's Inqovi widens its reach with FDA label expansion
BMS taps Anthropic’s Claude for enterprise-wide AI adoption to speed R&D, global workflows
Exclusive: Acceleron leaders and Westlake jumpstart new IPF biotech
Exclusive: Another I&I biotech, Gerhart-led cAMPfield, draws top-tier investors in $180M Series A
Inside Incyte’s $120 Million AI For Drug Development Deal
Eli Lilly teams up with Caitlin Clark to bounce sports courts into Indianapolis neighborhoods
Immunovant’s potential autoimmune ‘blockbuster’; Wave’s RNA editing update
A new ranking of pharma companies by R&D performance
Investment giants join forces to form largest healthcare firm on the globe - Pharmaceutical Technology
GHO Capital, CBC Group plan to merge, forming $21B healthcare investment firm
